- Home
- DALN vs NNVC Comparison
DALN vs NNVC Comparison
Compare DALN & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DALN
- NNVC
- Stock Information
- Founded
- DALN 1954
- NNVC 2005
- Country
- DALN United States
- NNVC United States
- Employees
- DALN N/A
- NNVC N/A
- Industry
- DALN Newspapers/Magazines
- NNVC Biotechnology: Pharmaceutical Preparations
- Sector
- DALN Consumer Discretionary
- NNVC Health Care
- Exchange
- DALN Nasdaq
- NNVC Nasdaq
- Market Cap
- DALN 24.6M
- NNVC 21.2M
- IPO Year
- DALN 2008
- NNVC N/A
- Fundamental
- Price
- DALN $6.64
- NNVC $1.51
- Analyst Decision
- DALN
- NNVC Strong Buy
- Analyst Count
- DALN 0
- NNVC 1
- Target Price
- DALN N/A
- NNVC $6.50
- AVG Volume (30 Days)
- DALN 79.0K
- NNVC 240.7K
- Earning Date
- DALN 11-12-2024
- NNVC 02-12-2025
- Dividend Yield
- DALN 2.41%
- NNVC N/A
- EPS Growth
- DALN N/A
- NNVC N/A
- EPS
- DALN N/A
- NNVC N/A
- Revenue
- DALN $128,286,000.00
- NNVC N/A
- Revenue This Year
- DALN N/A
- NNVC N/A
- Revenue Next Year
- DALN N/A
- NNVC N/A
- P/E Ratio
- DALN N/A
- NNVC N/A
- Revenue Growth
- DALN N/A
- NNVC N/A
- 52 Week Low
- DALN $2.98
- NNVC $1.00
- 52 Week High
- DALN $6.99
- NNVC $3.59
- Technical
- Relative Strength Index (RSI)
- DALN 67.81
- NNVC 56.79
- Support Level
- DALN $4.78
- NNVC $1.42
- Resistance Level
- DALN $4.74
- NNVC $1.57
- Average True Range (ATR)
- DALN 0.46
- NNVC 0.08
- MACD
- DALN 0.16
- NNVC 0.01
- Stochastic Oscillator
- DALN 86.74
- NNVC 69.05
About DALN DallasNews Corporation Series A
DallasNews Corp is a local news and information publishing company in Texas with commercial printing, distribution, and direct mail capabilities, as well as a presence in emerging media and digital marketing.
About NNVC NanoViricides Inc.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.